Effects of Tanreqing injection on the gut microbiota in healthy volunteers.

IF 4.6 2区医学 Q2 IMMUNOLOGY Frontiers in Cellular and Infection Microbiology Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI:10.3389/fcimb.2024.1428476

Shiyu Li, Wenxia Zhang, Sijie Liu, Yichen Zhou, Wei Liu, Weian Yuan, Min He

{"title":"Effects of Tanreqing injection on the gut microbiota in healthy volunteers.","authors":"Shiyu Li, Wenxia Zhang, Sijie Liu, Yichen Zhou, Wei Liu, Weian Yuan, Min He","doi":"10.3389/fcimb.2024.1428476","DOIUrl":null,"url":null,"abstract":"Objectives: Many studies have confirmed that antibacterial agents can disrupt the human gut microbiota. In China, Tanreqing injection (TRQ) is a drug with antibacterial activity that is widely used in the treatment of respiratory infections. However, its specific influence on gut microbiota remains unclear. This study aimed to investigate the effect of TRQ on the gut microbiota of healthy volunteers.Methods: Twelve healthy adults received 20 ml of TRQ intravenously daily for 7 consecutive days. At six timepoints (Pre, on D1, D3, D5, D7 and follow-up visit) fecal samples were collected and analyzed using 16S rRNA gene sequencing.Results: Eleven people were included in the analysis finally. TRQ did not significantly alter gut microbiota diversity or richness (Shannon and Simpson and Chao1 index) in healthy people during the intervention. Gut microbial structure was stable (weighted and unweighted Unifrac). Using a machine learning method based on PLS-DA analysis, the separation trend on D7 at the genus level was found, returning to baseline two days after discontinuation. The abundance of major genus fluctuated on D7 compared with that prior to treatment, including an increase of unclassified_f_Enterobacteriaceae (13.0611%), a decrease of Bifidobacterium and Escherichia-Shigella (6.887%, 10.487%). Functional prediction analysis did not reveal any significant difference.Conclusions: Our study showed short-term use of TRQ at conventional doses may not cause perturbations to the gut microbiota in healthy adults. This finding provides some useful information for the safe use of TRQ in the treatment of respiratory infections.Clinical trial registration: https://www.medicalresearch.org.cn/, identifier MR-31-24-014367.","PeriodicalId":12458,"journal":{"name":"Frontiers in Cellular and Infection Microbiology","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486765/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cellular and Infection Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcimb.2024.1428476","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Many studies have confirmed that antibacterial agents can disrupt the human gut microbiota. In China, Tanreqing injection (TRQ) is a drug with antibacterial activity that is widely used in the treatment of respiratory infections. However, its specific influence on gut microbiota remains unclear. This study aimed to investigate the effect of TRQ on the gut microbiota of healthy volunteers.

Methods: Twelve healthy adults received 20 ml of TRQ intravenously daily for 7 consecutive days. At six timepoints (Pre, on D1, D3, D5, D7 and follow-up visit) fecal samples were collected and analyzed using 16S rRNA gene sequencing.

Results: Eleven people were included in the analysis finally. TRQ did not significantly alter gut microbiota diversity or richness (Shannon and Simpson and Chao1 index) in healthy people during the intervention. Gut microbial structure was stable (weighted and unweighted Unifrac). Using a machine learning method based on PLS-DA analysis, the separation trend on D7 at the genus level was found, returning to baseline two days after discontinuation. The abundance of major genus fluctuated on D7 compared with that prior to treatment, including an increase of unclassified_f_Enterobacteriaceae (13.0611%), a decrease of Bifidobacterium and Escherichia-Shigella (6.887%, 10.487%). Functional prediction analysis did not reveal any significant difference.

Conclusions: Our study showed short-term use of TRQ at conventional doses may not cause perturbations to the gut microbiota in healthy adults. This finding provides some useful information for the safe use of TRQ in the treatment of respiratory infections.

Clinical trial registration: https://www.medicalresearch.org.cn/, identifier MR-31-24-014367.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

丹乐清注射液对健康志愿者肠道微生物群的影响

目的：许多研究证实，抗菌药会破坏人体肠道微生物群。在中国，丹瑞青注射液（TRQ）是一种具有抗菌活性的药物，被广泛用于治疗呼吸道感染。然而，它对肠道微生物群的具体影响仍不清楚。本研究旨在探讨丹瑞青对健康志愿者肠道微生物群的影响：方法：12 名健康成年人连续 7 天每天静脉注射 20 毫升 TRQ。在6个时间点（前期、D1、D3、D5、D7和随访）收集粪便样本，并使用16S rRNA基因测序进行分析：最终有 11 人参与了分析。在干预期间，TRQ 没有明显改变健康人肠道微生物群的多样性或丰富度（香农指数、辛普森指数和 Chao1 指数）。肠道微生物结构稳定（加权和非加权 Unifrac）。利用基于 PLS-DA 分析的机器学习方法，发现 D7 日在菌属水平上出现分离趋势，并在停药两天后恢复到基线水平。与治疗前相比，主要菌属的丰度在 D7 出现波动，包括未分类的_f_肠杆菌科菌属增加（13.0611%），双歧杆菌和埃希氏菌减少（6.887%，10.487%）。功能预测分析未发现任何显著差异：我们的研究表明，以常规剂量短期服用 TRQ 不会对健康成年人的肠道微生物群造成干扰。这一发现为安全使用TRQ治疗呼吸道感染提供了一些有用的信息。临床试验注册：https://www.medicalresearch.org.cn/，标识符为MR-31-24-014367。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Cellular and Infection Microbiology IMMUNOLOGY-MICROBIOLOGY

CiteScore

7.90

自引率

7.00%

发文量

1817

审稿时长

14 weeks

期刊介绍： Frontiers in Cellular and Infection Microbiology is a leading specialty journal, publishing rigorously peer-reviewed research across all pathogenic microorganisms and their interaction with their hosts. Chief Editor Yousef Abu Kwaik, University of Louisville is supported by an outstanding Editorial Board of international experts. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Cellular and Infection Microbiology includes research on bacteria, fungi, parasites, viruses, endosymbionts, prions and all microbial pathogens as well as the microbiota and its effect on health and disease in various hosts. The research approaches include molecular microbiology, cellular microbiology, gene regulation, proteomics, signal transduction, pathogenic evolution, genomics, structural biology, and virulence factors as well as model hosts. Areas of research to counteract infectious agents by the host include the host innate and adaptive immune responses as well as metabolic restrictions to various pathogenic microorganisms, vaccine design and development against various pathogenic microorganisms, and the mechanisms of antibiotic resistance and its countermeasures.